Skip to content

Pharmacologic treatment

TL;DR — No medicine gives substantial relief to most patients. NeuPSIG pooled NNTs for 50% relief were 6.4 for SNRIs, 7.2 gabapentin, 7.7 pregabalin and 10.6 capsaicin 8%; publication bias may overstate effects by about 10% (Finnerup 2015, PMID 25575710). Choice should be iterative and driven by comorbidity, adverse effects and function.

First-line classes

TCAs, SNRIs, gabapentin and pregabalin are common first-line choices (Finnerup 2015, PMID 25575710). AAN diabetic guidance recommends switching drug class after failure (Price 2022, PMID 34965987).

The pooled class estimates are not interchangeable treatment rankings. NeuPSIG's 50%-relief NNTs were 3.6 for TCAs, 6.4 for SNRIs, 7.2 for gabapentin and 7.7 for pregabalin, but the underlying trials differed in etiology, duration, dose, enrichment and outcome definition (Finnerup 2015, PMID 25575710). Direct comparative evidence is smaller: a 58-person crossover trial found good relief in 55% with amitriptyline and 59% with duloxetine, while dry mouth occurred in 55% versus 24% (Kaur 2011, PMID 21355098).

Class Main pharmacologic action Evidence-rich etiologies Selection pressure
TCA Serotonin/noradrenaline reuptake inhibition; additional channel effects Diabetic neuropathy, PHN Avoid or reduce dose with anticholinergic burden, orthostasis, conduction disease or falls risk
SNRI Serotonin/noradrenaline reuptake inhibition Diabetic neuropathy; duloxetine in CIPN Consider nausea, blood pressure, hepatic risk and withdrawal
Gabapentinoid α2δ calcium-channel ligand PHN, diabetic neuropathy; pregabalin in SCI Renal adjustment; sedation, edema, weight gain and misuse risk
Sodium-channel blocker State-dependent reduction of ectopic firing Trigeminal neuralgia; heterogeneous peripheral pain Drug-specific cardiac, hepatic, dermatologic and interaction risks

Gabapentin

Across 37 studies/5,914 participants, evidence is strongest in PHN and painful diabetic neuropathy; dizziness and somnolence are common (Wiffen 2017, PMID 28597471).

Pregabalin

Forty-five studies/11,906 participants showed condition- and dose-dependent benefit; PHN 300 mg produced ≥30% relief in 50% versus 25%, NNT 3.9 (Derry 2019, PMID 30673120).

A four-period placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in diabetic neuropathic pain found no significant analgesic difference among the active drugs. Secondary outcomes separated them: pregabalin improved sleep continuity, whereas duloxetine increased wake time and reduced total sleep time; adverse events were most frequent with pregabalin (Boyle 2012, PMID 22991449). This is a practical reason to match a class to the dominant comorbidity rather than infer that similar mean analgesia makes the medicines clinically equivalent.

Duloxetine

Painful diabetic neuropathy ≥50% relief RR was 1.73, NNT 5 (4–7) at 12 weeks (Lunn 2014, PMID 24385423).

Etiology matters. In painful chemotherapy-induced peripheral neuropathy, duloxetine reduced average pain by 1.06 points versus 0.34 with placebo over five weeks; the between-group mean difference was 0.73 (95% CI 0.26–1.20), and 59% versus 38% reported any pain reduction (Smith 2013, PMID 23549581). ASCO consequently identifies duloxetine as the only agent with appropriate evidence for established painful CIPN while emphasizing that benefit is limited (Loprinzi 2020, PMID 32663120).

Combination

OPTION-DM found similar pathways and greater improvement with combination rescue (Tesfaye 2022, PMID 36007534); COMBO-DN did not show significant superiority over high-dose monotherapy (Tesfaye 2013, PMID 23732189).

OPTION-DM randomized 140 participants to three 16-week pathways. Mean seven-day pain fell from 6.6 at baseline to 3.3 at week 16 in all pathways; there was no pathway difference, but adding a second drug for inadequate responders produced an additional mean 1.0-point reduction (Tesfaye 2022, PMID 36007534). The inference is sequencing support, not proof that every patient should start combination treatment.

A landmark 57-person crossover trial illustrates both the promise and cost of combination therapy: pain at maximum tolerated dose was 3.06/10 with gabapentin–morphine, 4.15 with gabapentin, 3.70 with morphine and 4.49 with active placebo; only 41 participants completed all periods, and constipation, sedation and dry mouth remained prominent (Gilron 2005, PMID 15800228). A later systematic review found that heterogeneous pairs, small samples and sparse long-term data prevent a universal combination hierarchy (Balanaser 2023, PMID 35588148).

Etiology-specific limits

Pooling all neuropathic pain can conceal genuine treatment-by-etiology differences.

Etiology Quantified evidence signal Boundary
Painful diabetic neuropathy Multiple classes reduce pain; direct trials show similar mean analgesia but different sleep/adverse-effect profiles (Boyle 2012, PMID 22991449) Most trials last weeks, not years
CIPN Duloxetine placebo-adjusted mean benefit 0.73/10 over five weeks (Smith 2013, PMID 23549581) Chemotherapy class and sensory phenotype may modify response
Phantom-limb pain Gabapentin pooled mean difference −1.16/10 (95% CI −1.94 to −0.38) across two small trials (Alviar 2016, PMID 27737513) Fourteen studies included only 269 participants; function and durability were poorly reported
SCI pain Network estimates favor anticonvulsants, but comparisons are based on 15 small trials and adverse effects are common (Mei 2022, PMID 35468995) Indirect rankings are not head-to-head proof
Trigeminal neuralgia Carbamazepine/oxcarbazepine remain syndrome-specific anchors (Bendtsen 2019, PMID 30860637) Evidence and safety logic should not be generalized to distal polyneuropathy

Opioids/cannabis

Across chronic pain, opioids improved pain by −0.69/10 and function by 2.04/100, below prespecified average minimal differences (Busse 2018, PMID 30561481). Cannabis evidence is low quality with harms (Mücke 2018, PMID 29513392).

Short neuropathic-pain trials can demonstrate analgesia without resolving dependence, overdose, tolerance or endocrine outcomes. That asymmetry explains why guideline panels may acknowledge efficacy yet recommend against routine initiation or place tramadol/strong opioids later (Finnerup 2015, PMID 25575710); (Price 2022, PMID 34965987). Cannabis reviews similarly find small short-term signals alongside dizziness, somnolence and psychiatric adverse events, with little evidence about long-term function (Mücke 2018, PMID 29513392); (Petzke 2022, PMID 34802112).

Safety matrix

Class Main concern
TCA Anticholinergic, cardiac, falls
SNRI Nausea, BP, withdrawal
Gabapentinoid Sedation, edema, renal dosing
Tramadol Serotonergic toxicity, dependence
Opioid Overdose, dependence, endocrine effects
Cannabis CNS/psychiatric adverse effects

Response rule

Predefine adequate dose/duration, pain and function target, and stopping rule. Treatment response does not validate diagnosis (Hansson 2009, PMID 19324579).

Evidence interpretation map

The table makes the evidence role and inferential boundary explicit; it is not a replacement for the full reports.

PMID Year Evidence role What it cannot establish alone
25575710 2015 Cross-etiology network meta-analysis and NNT framework Best drug for an individual or long-term safety
22991449 2012 Direct comparison including sleep physiology Durable superiority; treatment periods were short
36007534 2022 Pragmatic sequence-and-add-on comparison Superiority of one pathway or immediate dual therapy
15800228 2005 Placebo-controlled combination proof of concept Net benefit of chronic opioid combination use
23549581 2013 Placebo-controlled CIPN trial General efficacy across all neuropathic etiologies
27737513 2016 Etiology-specific systematic review Precise rankings from a total sample of 269

Explicit controversies

  1. Class-first versus phenotype-first care. Guidelines support class switching because average class effects are modest (Price 2022, PMID 34965987). Oxcarbazepine data suggest a larger effect in an “irritable nociceptor” phenotype, but a later lacosamide trial did not replicate phenotype prediction (Demant 2014, PMID 25139589); (Carmland 2024, PMID 37565715). The predictive value of QST therefore remains unresolved.
  2. Combination escalation versus high-dose monotherapy. OPTION-DM supports adding a second first-line drug after partial response (Tesfaye 2022, PMID 36007534), whereas COMBO-DN did not demonstrate significant superiority of duloxetine–pregabalin over high-dose monotherapy (Tesfaye 2013, PMID 23732189). Different designs and doses prevent a simple contradiction from being “resolved” by vote counting.
  3. Analgesic efficacy versus acceptable recommendation. Opioids can reduce pain in short trials, including combination studies (Gilron 2005, PMID 15800228), but broader chronic-pain effect sizes are small and long-term harms are insufficiently represented (Busse 2018, PMID 30561481). This is why efficacy and guideline placement diverge.

Minimum reporting controls

Domain Required report
Case definition Possible, probable or definite neuropathic pain
Etiology Lesion/disease and diagnostic evidence
Distribution Focal, length-dependent, dermatomal, at-level or below-level
Baseline phenotype Negative and positive sensory signs
Comparator Placebo/sham, active care or natural history
Exposure Dose, duration, adherence and co-interventions
Benefit Mean change plus ≥30% and ≥50% responders where applicable
Function Sleep, mobility, participation and patient global change
Harm Adverse events, withdrawals and serious events
Durability Follow-up after treatment and attrition
Subgroups Prespecified interaction test, not within-group significance
Missingness Denominator and imputation method

Reporting cautions

  • Do not infer lesion presence from a symptom descriptor.
  • Do not convert a group-average association into an individual diagnostic rule.
  • Do not treat statistical significance as clinically important benefit.
  • Do not compare NNTs without checking outcome threshold, duration and population.
  • Do not interpret an inactive or completed registry record as proof of efficacy.
  • Do not merge painful and painless neuropathy outcomes.
  • Do not omit adverse-event withdrawals from responder interpretation.
  • Do not call a post hoc subgroup predictive without an interaction test.
  • Do not generalize a focal peripheral result to central neuropathic pain.
  • State when evidence is short-term, indirect or restricted to a selected cohort.

Open questions

  • Which sequence maximizes net benefit?
  • Who benefits from combination therapy?
  • What is durability beyond trials?
  • Can phenotype predict class response?

References

  1. Finnerup NB, Attal N, Haroutounian S, et al.. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-73. PMID 25575710
  2. Price R, Smith D, Franklin G, et al.. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology. 2022;98:31-43. PMID 34965987
  3. Wiffen PJ, Derry S, Bell RF, et al.. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938. PMID 28597471
  4. Derry S, Bell RF, Straube S, et al.. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076. PMID 30673120
  5. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;2014:CD007115. PMID 24385423
  6. Tesfaye S, Sloan G, Petrie J, et al.. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet. 2022;400:680-690. PMID 36007534
  7. Tesfaye S, Wilhelm S, Lledo A, et al.. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616-2625. PMID 23732189
  8. Busse JW, Wang L, Kamaleldin M, et al.. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. JAMA. 2018;320:2448-2460. PMID 30561481
  9. Mücke M, Phillips T, Radbruch L, et al.. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182. PMID 29513392
  10. Hansson PT, Attal N, Baron R, et al.. Toward a definition of pharmacoresistant neuropathic pain. Eur J Pain. 2009;13:439-40. PMID 19324579
  11. Moisset X, Bouhassira D, Avez Couturier J, et al.. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev Neurol (Paris). 2020;176:325-352. PMID 32276788
  12. Attal N, Cruccu G, Baron R, et al.. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88. PMID 20402746
  13. Moulin D, Boulanger A, Clark AJ, et al.. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328-35. PMID 25479151
  14. Knezevic NN, Jovanovic F, Candido KD, et al.. Oral pharmacotherapeutics for the management of peripheral neuropathic pain conditions - a review of clinical trials. Expert Opin Pharmacother. 2020;21:2231-2248. PMID 32772737
  15. Mayoral V, Galvez R, Ferrándiz M, et al.. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety. Front Pain Res (Lausanne). 2024;5:1513597. PMID 39839199
  16. Meaadi J, Obara I, Eldabe S, et al.. The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. Int J Clin Pharm. 2023;45:556-565. PMID 36848024
  17. Mian MU, Afzal M, Butt AA, et al.. Neuropharmacology of Neuropathic Pain: A Systematic Review. Cureus. 2024;16:e69028. PMID 39385859
  18. Petzke F, Tölle T, Fitzcharles MA, et al.. Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS Drugs. 2022;36:31-44. PMID 34802112
  19. Gierthmühlen J, Baron R. Neuropathic Pain. Semin Neurol. 2016;36:462-468. PMID 27704502
  20. Smith EM, Pang H, Cirrincione C, et al.. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359-67. PMID 23549581
  21. Balanaser M, Carley M, Baron R, et al.. Combination pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis. Pain. 2023;164:230-251. PMID 35588148
  22. Snedecor SJ, Sudharshan L, Cappelleri JC, et al.. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68:900-18. PMID 24698515
  23. Brix Finnerup N, Hein Sindrup S, Staehelin Jensen T. Management of painful neuropathies. Handb Clin Neurol. 2013;115:279-90. PMID 23931787
  24. Moisset X. Neuropathic pain: Evidence based recommendations. Presse Med. 2024;53:104232. PMID 38641202
  25. Thouaye M, Yalcin I. Neuropathic pain: From actual pharmacological treatments to new therapeutic horizons. Pharmacol Ther. 2023;251:108546. PMID 37832728
  26. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324-1334. PMID 15800228
  27. Kaur H, Hota D, Bhansali A, et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011;34:818-822. PMID 21355098
  28. Boyle J, Eriksson MEV, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35:2451-2458. PMID 22991449
  29. Alviar MJM, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev. 2016;10:CD006380. PMID 27737513
  30. Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014;155:2263-2273. PMID 25139589
  31. Carmland ME, Kreutzfeldt MD, Holbech JV, et al. The effect of lacosamide in peripheral neuropathic pain: a randomized, double-blind, placebo-controlled, phenotype-stratified trial. Eur J Pain. 2024;28:105-119. PMID 37565715
  32. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38:3325-3348. PMID 32663120
  33. Mei L, Fengqun M, Zhengyao Z, et al. Efficacy and safety of different drug treatments in patients with spinal-cord injury-related neuropathic pain: a network meta-analysis. Spinal Cord. 2022;60:943-953. PMID 35468995
  34. Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019;26:831-849. PMID 30860637